The LumiSystem is a detection tool that uses fluorescence imaging technology during lumpectomy, offering a more complete resection vs other detection systems that evaluate tissue after surgical ...
Katrina Cooke and Ashley Dostefano share their personal journeys, reflecting on the challenges they faced, the victories they ...
Atezolizumab (Tecentriq) plus chemotherapy after surgery did not improve survival in high-risk triple-negative breast cancer, according to a global phase 3 trial.
A phase 3 clinical trial has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved – almost ...
The University of Iowa study is analyzing the period between breast cancer diagnosis and treatment, when many patients feel ...
Hailee Steinfeld is teaming up with Novartis to raise awareness about breast cancer with an empowering Super Bowl 59 ...
Have you ever wondered why some types of breast cancer are harder to detect than others? Breast cancer is a reality that affects millions of women around the world, and in India, its prevalence has ...
The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...
Enhertu first secured approval in 2019 for patients with high levels of HER2, a protein that promotes cancer cell growth. In ...
Triple negative breast cancer wreaks a particularly heavy toll in certain regions and populations, with stark differences in both incidence and survival rates ...
Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.
Jan. 22, 2025 — Despite significant therapeutic advances, breast cancer remains a leading cause of cancer-related death in women. Treatment typically involves surgery and follow-up hormone ...